Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
StockNews.AI · 2 hours
AI Summary
Caribou Biosciences reported strong ANTLER phase 1 results for vispa-cel in second-line LBCL, including 82% ORR and 67% CR with a 17.1-month median PFS, with no GvHD and limited high-grade toxicities. The data support moving to a pivotal ANTLER-3 trial (~250 CD19-naïve 2L LBCL patients) using a single 80 million dose. An EHA presentation (June 12, 2026) and the phase 3 design alignment provide near-term catalysts for CRBU shares, though data are from a small cohort (N=27).
Sentiment Rationale
Strong early efficacy and safety signals for vispa-cel, plus clear near-term catalysts (EHA data and ANTLER-3 progression) could drive positive sentiment and valuation re-rating for CRBU, despite small sample size and early-stage data.
Trading Thesis
Bullish in the near term on EHA data and ANTLER-3 progress; potential re-rating within 1–3 months.
Market-Moving
- EHA presentation on June 12, 2026 could trigger a CRBU upside reaction.
- ANTLER-3 trial design alignment may lower regulatory risk and accelerate value realization.
- Strong 2L LBCL efficacy signals contrast with autologous CAR-T limits, supporting market interest.
Key Facts
- Vispa-cel shows 82% ORR, 67% CR in 2L LBCL; mPFS 17.1 months.
- No GvHD; 4% ≥Gr 3 CRS; safety supports outpatient use.
- ANTLER-3 phase 3 targets ~250 CD19-naïve 2L LBCL; single 80M dose.
- EHA presentation on June 12, 2026, 5:15-6:30pm CEST in Stockholm.
- Data cutoff was March 6, 2026; RP2D is 80 million vispa-cel cells.
Companies Mentioned
- Caribou Biosciences, Inc. (CRBU): Reported positive ANTLER data; near-term catalysts include EHA presentation and ANTLER-3 development.
Industry News
Industry News. The report highlights a clinical-stage CRISPR CAR-T candidate with an off-the-shelf, single-dose approach, potentially disrupting autologous CAR-T access barriers and expanding addressable care in LBCL; fits current biotechnology sector interest in next-gen cell therapies.